Approval Application for ANCA-Associated Vasculitis Drug Amended by Developer
source: pixabay.com

Approval Application for ANCA-Associated Vasculitis Drug Amended by Developer

According to a story from ANCA Vasculitis News, the biopharmaceutical company ChemoCentryx has recently made an amendment to its approval application for its investigational therapy. This therapy, called avacopan, is…

Continue Reading Approval Application for ANCA-Associated Vasculitis Drug Amended by Developer
Managing Antineutrophil Cytoplasmic Antibody (ANCA) Vasculitis
source: pixabay.com

Managing Antineutrophil Cytoplasmic Antibody (ANCA) Vasculitis

According to an article in Healio, Dr. Anisha Dua recently addressed attendees at the ACR Clinical Symposium on the subject of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Dr. Dua is the…

Continue Reading Managing Antineutrophil Cytoplasmic Antibody (ANCA) Vasculitis

Study of the Week: Nucala’s Effectiveness in EGPA Confirmed in Real-World Study

Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…

Continue Reading Study of the Week: Nucala’s Effectiveness in EGPA Confirmed in Real-World Study